Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer

被引:25
作者
Nath, Arijit [1 ]
Mitra, Soham [2 ]
Mistry, Tanuma [3 ]
Pal, Ranita [3 ]
Nasare, Vilas D. [3 ]
机构
[1] Kalinga Inst Ind Technol KIIT Deemed Univ, Bhubaneswar 751024, Odisha, India
[2] Natl Inst Technol, Dept Biotechnol & Med Engn, Rourkela 769008, Odisha, India
[3] Chittaranjan Natl Canc Inst, Dept Pathol & Canc Screening, 37 SP Mukherjee Rd, Kolkata 700026, India
关键词
TNBC; Heterogeneity; Chemoresistance; Signaling pathways; Molecular targets and therapeutics; HEDGEHOG SIGNALING PATHWAY; HYPOXIA-INDUCIBLE FACTORS; HEMATOPOIETIC STEM-CELLS; TUMOR-INITIATING CELLS; NEOADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; HIPPO PATHWAY; KINASE; THERAPY; AURORA;
D O I
10.1007/s12032-021-01610-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer (BC), which shows immunohistochemically negative expression of hormone receptor i.e., Estrogen receptor and Progesterone receptor along with the absence of Human Epidermal Growth Factor Receptor-2 (HER2/neu). In Indian scenario the prevalence of BC is 26.3%, whereas, in West Bengal the cases are of 18.4%. But the rate of TNBC has increased up to 31% and shows 27% of total BC. Conventional chemotherapy is effective only in the initial stages but with progression of the disease the effectivity gets reduced and shown almost no effect in later or advanced stages of TNBC. Thus, TNBC patients frequently develop resistance and metastasis, due to its peculiar triple-negative nature most of the hormonal therapies also fails. Development of chemoresistance may involve various factors, such as, TNBC heterogeneity, cancer stem cells (CSCs), signaling pathway deregulation, DNA repair mechanism, hypoxia, and other molecular factors. To overcome the challenges to treat TNBC various targets and molecules have been exploited including CSCs modulator, drug efflux transporters, hypoxic factors, apoptotic proteins, and regulatory signaling pathways. Moreover, to improve the targets and efficacy of treatments researchers are emphasizing on targeted therapy for TNBC. In this review, an effort has been made to focus on phenotypic and molecular variations in TNBC along with the role of conventional as well as newly identified pathways and strategies to overcome challenge of chemoresistance.
引用
收藏
页数:33
相关论文
共 208 条
[1]  
Al-Rashed F., 2021, SCI REP-UK, V11, P1
[2]   BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells [J].
Alhoshani, Ali ;
Alatawi, Fahad O. ;
Al-Anazi, Fawaz E. ;
Attafi, Ibraheem M. ;
Zeidan, Asad ;
Agouni, Abdelali ;
El Gamal, Heba M. ;
Shamoon, Licia S. ;
Khalaf, Sarah ;
Korashy, Hesham M. .
ONCOTARGETS AND THERAPY, 2020, 13 :13357-13370
[3]   The role of photodynamic therapy on multidrug resistant breast cancer [J].
Aniogo, Eric Chekwube ;
George, Blassan Plackal Adimuriyil ;
Abrahamse, Heidi .
CANCER CELL INTERNATIONAL, 2019, 19 (1)
[4]   Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2 [J].
Arumugam, Arunkumar ;
Subramani, Ramadevi ;
Nandy, Sushmita Bose ;
Terreros, Daniel ;
Dwivedi, Alok Kumar ;
Saltzstein, Edward ;
Lakshmanaswamy, Rajkumar .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2019, 51 (1) :1-13
[5]   TGFβ/TNFα-Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype [J].
Asiedu, Michael K. ;
Ingle, James N. ;
Behrens, Marshall D. ;
Radisky, Derek C. ;
Knutson, Keith L. .
CANCER RESEARCH, 2011, 71 (13) :4707-4719
[6]   The Varied Roles of Notch in Cancer [J].
Aster, Jon C. ;
Pear, Warren S. ;
Blacklow, Stephen C. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 12, 2017, 12 :245-275
[7]   Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance [J].
Balko, Justin M. ;
Cook, Rebecca S. ;
Vaught, David B. ;
Kuba, Maria G. ;
Miller, Todd W. ;
Bhola, Neil E. ;
Sanders, Melinda E. ;
Granja-Ingram, Nara M. ;
Smith, J. Joshua ;
Meszoely, Ingrid M. ;
Salter, Janine ;
Dowsett, Mitch ;
Stemke-Hale, Katherine ;
Gonzalez-Angulo, Ana M. ;
Mills, Gordon B. ;
Pinto, Joseph A. ;
Gomez, Henry L. ;
Arteaga, Carlos L. .
NATURE MEDICINE, 2012, 18 (07) :1052-+
[8]   Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy [J].
Baran, Natalia ;
Konopleva, Marina .
CLINICAL CANCER RESEARCH, 2017, 23 (10) :2382-2390
[9]   Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial [J].
Bardia, Aditya ;
Parton, Marina ;
Kuemmel, Sherko ;
Estevez, Laura G. ;
Huang, Chiun-Sheng ;
Cortes, Javier ;
Ruiz-Borrego, Manuel ;
Telli, Melinda L. ;
Martin-Martorell, Paloma ;
Lopez, Rafael ;
Beck, J. Thaddeus ;
Ismail-Khan, Roohi ;
Chen, Shin-Cheh ;
Hurvitz, Sara A. ;
Mayer, Ingrid A. ;
Carreon, Daniel ;
Cameron, Scott ;
Liao, Serena ;
Baselga, Jose ;
Kim, Sung-Bae .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (31) :3126-+
[10]   Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer [J].
Basudhar, Debashree ;
Glynn, Sharon A. ;
Greer, Madison ;
Somasundaram, Veena ;
No, Jae Hong ;
Scheiblin, David A. ;
Garrido, Pablo ;
Heinz, William F. ;
Ryan, Aideen E. ;
Weiss, Jonathan M. ;
Cheng, Robert Y. S. ;
Ridnour, Lisa A. ;
Lockett, Stephen J. ;
McVicar, Daniel W. ;
Ambs, Stefan ;
Wink, David A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (49) :13030-13035